BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32338903)

  • 1. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
    Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
    Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
    Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.
    Aguilar A; Zheng K; Xu T; Xu S; Huang L; Fernandez-Salas E; Liu L; Bernard D; Harvey KP; Foster C; McEachern D; Stuckey J; Chinnaswamy K; Delproposto J; Kampf JW; Wang S
    J Med Chem; 2019 Jul; 62(13):6015-6034. PubMed ID: 31244110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.
    Zhang M; Aguilar A; Xu S; Huang L; Chinnaswamy K; Sleger T; Wang B; Gross S; Nicolay BN; Ronseaux S; Harvey K; Wang Y; McEachern D; Kirchhoff PD; Liu Z; Stuckey J; Tron AE; Liu T; Wang S
    J Med Chem; 2021 Jul; 64(14):10333-10349. PubMed ID: 34196551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
    Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
    Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Progress of Small Molecule Menin-MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia.
    Lei H; Zhang SQ; Fan S; Bai HR; Zhao HY; Mao S; Xin M
    J Med Chem; 2021 Nov; 64(21):15519-15533. PubMed ID: 34726905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
    Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
    Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges and opportunities in targeting the menin-MLL interaction.
    Cierpicki T; Grembecka J
    Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
    Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
    Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).
    Borkin D; Pollock J; Kempinska K; Purohit T; Li X; Wen B; Zhao T; Miao H; Shukla S; He M; Sun D; Cierpicki T; Grembecka J
    J Med Chem; 2016 Feb; 59(3):892-913. PubMed ID: 26744767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
    Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
    Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of
    Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
    J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
    Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
    Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based screening and optimization of cytisine derivatives as inhibitors of the menin-MLL interaction.
    Zhong HJ; Lee BR; Boyle JW; Wang W; Ma DL; Hong Chan PW; Leung CH
    Chem Commun (Camb); 2016 Apr; 52(34):5788-91. PubMed ID: 27004852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
    Borkin D; Klossowski S; Pollock J; Miao H; Linhares BM; Kempinska K; Jin Z; Purohit T; Wen B; He M; Sun D; Cierpicki T; Grembecka J
    J Med Chem; 2018 Jun; 61(11):4832-4850. PubMed ID: 29738674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
    Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
    ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Novel Inhibitors Targeting the Menin-Mixed Lineage Leukemia Interface Using Pharmacophore- and Docking-Based Virtual Screening.
    Xu Y; Yue L; Wang Y; Xing J; Chen Z; Shi Z; Liu R; Liu YC; Luo X; Jiang H; Chen K; Luo C; Zheng M
    J Chem Inf Model; 2016 Sep; 56(9):1847-55. PubMed ID: 27513308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.